NCT07787247Recruiting
Feasibility of Remote Monitoring of Patients With Myasthenia Gravis
Pilot Study: Feasibility of Remote Monitoring of Patients With Myasthenia Gravis
Source: ClinicalTrials.gov · Last updated 5 Oct 2026
Brief summary (registry, in English)
Myasthenia gravis is an autoimmune neuromuscular disorder characterized by fluctuating weakness, which can worsen suddenly without a clear predictor. The hypothesis is that continuous monitoring of key aspects of patient physiology and activity coupled to rigorous telemedicine-performed examination has the potential to detect MG worsening which requires change in treatment with the benefit of avoiding need for hospitalization or emergent therapy. This study is to evaluate the reliability of the technology and patient compliance to the monitoring program
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 18 (estimated)
- First submitted
- 17 Aug 2026
- Start date
- 19 Aug 2026
- Primary completion date
- 31 Oct 2028
- Lead sponsor
- George Washington University
- Diseases
- Myasthenia gravis
- NCT number
- NCT07787247
What you commit to
- Study type: Observational
- Planned participants: 18
- From 19 Aug 2026 to the primary completion date, 31 Oct 2028
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Disease Specific Exclusion Criteria
- Any significant medical/psychiatric condition that, in the opinion of the Investigator, may interfere with interpretation of subject evaluation(s) or protocol compliance
- Any disorder that could limit ability to assess myasthenia gravis specific deficits (not including planned or recent thymectomy)
Other
- Inability to comply with study protocol for monitoring
- Current MGFA Severity Class IVb or V, or patients in remission with MGFA Class 0
- Pregnancy, based on the evaluator's judgment, if the subject is deemed not safe to undergo evaluation or comply with study visit requirements.
- Lack of effective internet connection or ability to use study telemedicine station and monitors
- Home environment prevents use of study equipment
- Likelihood of leaving DC, Maryland, or Virginia area in year after initiation of study
- Subject is already participating in a research study -
Who the study is looking for
- Subject
- Has the capacity to understand and sign an informed consent form
- ≥18 years old
- Diagnosed with acquired autoimmune MG based on clinical syndrome and seropositivity for MG associated autoantibodies (AChR binding, MuSK, or LRP4 antibodies), and/or a decremental response on repetitive nerve stimulation, positive single fiber electromyography (EMG) or positive edrophonium test
- Subject has been previously evaluated in a face-to-face clinical encounter at participating study site or referral site within the prior 3 years
- Primary language is English, or equivalent level of English language fluency
- Required disease severity range previously judged by the Investigator. MGFA class 1-4a within 3 years of diagnosis without other chronic medical conditions, which compromise participation.
- Having MG-ADL score above 2 upon entrance to study
- Patients considered by study PI not to require hospitalization at time of entrance
- The patient has internet capability and a smart phone compatible with the apps required by the study.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| The George Washington University Coordinator of this site? Confirm its status | Washington D.C. | United States | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.